Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the study drug, romiplostim, helps low platelet count
caused by standard chemotherapy treatment for lymphoma. This study will also look at whether
romiplostim can prevent the need for chemotherapy dose delays, chemotherapy dose reductions,
and platelet transfusions. In addition, we will determine how safe it is to give romiplostim
to people with lymphoma who have low platelet count from chemotherapy.